- ANGLE plc (OTCQX:ANPCY) successfully passed all resolutions at its 2025 Annual General Meeting.
- Detailed voting results will be made available on the company's website.
- ANGLE plc is renowned for its liquid biopsy innovations with the Parsortix®PC1 System.
ANGLE plc (OTCQX:ANPCY), a leader in liquid biopsy technology, announced that all resolutions proposed at the company's 2025 Annual General Meeting, held on June 30, 2025, have been approved. Shareholders can expect the detailed results of the voting to be published on ANGLE's corporate website shortly.
The Guildford, Surrey-based company is celebrated for its innovative circulating tumor cell (CTC) solutions, particularly the Parsortix®PC1 System. This FDA-cleared and patent-protected technology facilitates comprehensive analysis of samples through CTC harvesting, allowing for whole cell imaging, proteomic analysis, and extensive genomic and transcriptomic molecular investigations.
ANGLE's business operations span clinical services and diagnostic products, with a focus on custom assay development and clinical trial testing for pharmaceutical companies. The Parsortix system has gained substantial credibility, backed by over 100 peer-reviewed publications demonstrating its efficacy.
For further details, visit ANGLE plc's official website or contact their team for more specific inquiries.
